| abstract |
A pyridopyrimidinone or pyridopyridone compound having a structure of the formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof. This kind of compound can inhibit the activity of EGFR cysteine mutated into serine (EGFR C797S) mutant, but it is weak to wild-type EGFR, which can effectively inhibit the growth of non-small cell lung cancer tumor cells, and can be used for preparation. Anti-tumor drugs, mainly used in the third-generation EGFR small molecule inhibitors against non-small cell lung cancer drugs Osimertinib (AZD9291), Olmutinib (HM6171), Rociletinib (9, CO-1686) induced 797th cysteine The gene is mutated to the clinical resistance of serine (C797S), which is selective for wild-type non-small cell lung cancer. (I) |